Emil von Behring

Emil von Behring
Fritz Schuhmann, Hofphotograph Bad Kissingen · Public domain · source
Name	Emil von Behring
Birth date	15 March 1854
Birth place	Hansdorf, West Prussia
Death date	31 March 1917
Death place	Marburg, Hesse-Nassau
Nationality	German
Field	Immunology, Bacteriology, Physiology
Institutions	Königlich Preußisches Institut für Infektionskrankheiten, University of Berlin, University of Marburg
Alma mater	Charité, University of Berlin
Known for	Serum therapy for diphtheria and tetanus; Nobel Prize in Physiology or Medicine (1901)
Awards	Nobel Prize (1901)

Emil von Behring Emil von Behring was a German physiologist and bacteriologist whose work established the principle of serum therapy and laid foundations for modern immunology. He developed therapeutic antisera against diphtheria and tetanus, collaborated with contemporaries at institutions such as the Robert Koch Institute and the University of Marburg, and received the 1901 Nobel Prize in Physiology or Medicine for his achievements. His research intersected with figures like Robert Koch, Paul Ehrlich, Kitasato Shibasaburo, and institutions including the Charité and the German Empire's public health apparatus.

Early life and education

Born in Hansdorf, West Prussia, Behring came of age during the era of the German Empire's consolidation following the Franco-Prussian War. He entered medical training at the Charité in Berlin and completed studies influenced by mentors at the Königlich Preußisches Institut für Infektionskrankheiten, where he worked under and alongside investigators connected to Robert Koch and the bacteriological movement centered on the Institut Pasteur and European research centers. His early exposure to outbreaks of infectious diseases and the laboratory culture of the University of Berlin oriented him toward experimental approaches to host resistance and passive immunity, aligning with contemporaneous inquiries by researchers in London, Paris, and Vienna.

Research and scientific contributions

Behring’s experiments explored humoral factors mediating resistance to infectious agents, building on prior observations from workers such as Louis Pasteur, Émile Roux, and colleagues in the emerging field of bacteriology. In collaboration with Kitasato Shibasaburo, he demonstrated that sera from animals immunized against Clostridium tetani and Corynebacterium diphtheriae conferred protection when transferred to susceptible hosts, a concept resonant with the immunological theories elaborated by Paul Ehrlich and debated in laboratories at the Robert Koch Institute and the Institut Pasteur network. Behring applied quantitative assays and animal models, comparing serum potency across preparations and advancing laboratory standardization practices that influenced vaccine and antisera production in industrial settings, including work later linked to companies in Frankfurt am Main and Hamburg.

His methodological contributions encompassed serum standardization, potency testing in laboratory animals, and protocols for large-scale antisera manufacture, which intersected with regulatory and scientific institutions such as the Prussian Ministry of Cultures and Education and municipal public health services in Berlin. Behring’s publications circulated among scientific societies including the German Academy of Sciences Leopoldina and influenced researchers in St. Petersburg, Vienna, and Rome.

Development of diphtheria and tetanus therapies

Investigating diphtheria, Behring collaborated with laboratory partners to isolate the pathogenic toxin and to demonstrate that neutralizing antibodies in convalescent or immunized animals’ sera could prevent disease. These findings paralleled immunochemical work by Émile Roux and clinical observations from pediatric hospitals such as those in Berlin and Vienna. Behring organized protocols for immunizing horses to produce high-titer antisera, enabling passive immunotherapy for human patients in hospitals across Germany and later internationally in centers from New York to Tokyo. He also extended serum approaches to tetanus prophylaxis, drawing upon microbial studies by Kitasato Shibasaburo and antiseptic practices inspired by surgeons in London and Paris.

The commercialization and distribution of therapeutic antisera involved partnerships and controversies involving patenting, manufacturing, and pricing, bringing Behring into contact with industrialists and medical bureaucracies in Germany and abroad. Clinical trials and public health campaigns in municipal hospitals, charitable institutions, and military medical services during peacetime and wartime documented reductions in mortality from diphtheria and tetanus where antisera were deployed, influencing public health strategies in nations including the United Kingdom, France, and the United States.

Nobel Prize and recognition

In 1901 Behring was awarded the inaugural Nobel Prize in Physiology or Medicine in recognition of his work on serum therapy, sharing scientific prominence with contemporaries such as Paul Ehrlich and raising international interest from societies like the Royal Society and the Académie des Sciences. The prize catalyzed honors from universities and academies across Europe, including appointments and honorary doctorates from the University of Marburg, the University of Vienna, and recognition from the Prussian Academy of Sciences. Behring was later ennobled, reflecting the German Empire’s practice of conferring titles to distinguished scientists, and his name became associated with institutes, prizes, and departments in medical faculties across Germany and allied networks.

Later career and legacy

As director of the Institute for Serum Research and Serum Testing in Marburg, Behring oversaw expansion of production facilities and training that influenced later vaccine development at institutions linked to the Robert Koch Institute and industrial manufacturers in Germany and abroad. His work anticipated and shaped subsequent advances by researchers such as Alexander Fleming, Felix d’Herelle, and Albert Calmette in antimicrobial and immunological therapies, and informed regulatory standards adopted by public health bodies in Europe and the United States.

Behring’s legacy persists through eponymous foundations, museums, and research chairs at universities such as the University of Marburg and through the continued use of passive immunotherapy concepts in modern medicine, including treatments developed for emerging infections by institutions like the World Health Organization and national health agencies. His career exemplifies the transition from nineteenth-century bacteriology to twentieth-century immunology, linking laboratory discovery, clinical application, and institutional development across a network of scientists and centers from Berlin to Tokyo.

Category:German physiologists Category:Nobel laureates in Physiology or Medicine